Spatial heterogeneity of MRI response to first-line hormonal therapy to predict progression-free survival in metastatic breast cancer.

被引：0
|
作者：
Kosmin, Michael
Makris, Andreas
Sokhi, Heminder
Thijssen, Toon
Padhani, Anwar R.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Acad Oncol Unit, Pinner, England
[3] Paul Strickland Scanner Ctr, Northwood, Middx, England
[4] Paul Strickland Scanner Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12544
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12544
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Elevated pretreatment serum biomarkers and correlation with progression-free(PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer
    Ali, Suhail M.
    Leitzel, Kim
    Anyanwu, Uchechi
    Hou, Hui Ying
    Evans, Matthew Stephen
    Shrivastava, Vika
    Koeztler, Wolfgang
    Fuchs, Eva-Maria
    Esteva, Francisco J.
    Carney, Walter P.
    Lipton, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment
    Goncalves, A.
    Deblock, M.
    Esterni, B.
    Toiron, Y.
    Tarpin, C.
    Charaffe-Jauffret, E.
    Chabannon, C.
    Extra, J. M.
    Viens, P.
    Borg, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Hepatic and Overall Progression-Free Survival after Percutaneous Hepatic Perfusion as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma
    Ghali, Helana
    Dugan, Michelle M.
    Aflatooni, Shaliz
    Boby, Aleena
    DePalo, Danielle K.
    Laborde, Jose
    Zager, Jonathan S.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S33 - S33
  • [34] PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - CLINICAL BENEFITS OF ACHIEVING A DEEP RESPONSE TO FIRST-LINE THERAPY
    Samp, J.
    Guerin, A.
    Foster, R.
    Meissner, B.
    Rokito, A.
    Enschede, S. H.
    Gauthier, G.
    HAEMATOLOGICA, 2017, 102 : 718 - 719
  • [35] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [36] IN ADVANCED/METASTATIC BREAST CANCER, IS PROGRESSION-FREE SURVIVAL A SURROGATE OUTCOME?
    Franca, A. C.
    Schroeder, L.
    Padilla, M.
    Meirelles, I
    Silva, A. S.
    Magliano, C.
    Santos, M.
    VALUE IN HEALTH, 2020, 23 : S477 - S478
  • [37] Doubling time of progression-free survival by palbociclib in metastatic breast cancer
    L'Allemain, Gilles
    BULLETIN DU CANCER, 2015, 102 (04) : 300 - 300
  • [38] Trastuzumab as first-line therapy for metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 776 - 776
  • [39] PERSONALIZED DISCRETE EVENT SIMULATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR FIRST-LINE DOUBLET CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
    Degeling, K.
    Wong, H. L.
    Johns, J.
    Koffijberg, H.
    Gibbs, P.
    IJzerman, M.
    VALUE IN HEALTH, 2019, 22 : S96 - S96
  • [40] Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer
    Eleazar Omar Macedo-Pérez
    Vicente Morales-Oyarvide
    Víctor Osvaldo Mendoza-García
    Yuzmiren Dorantes-Gallareta
    Diana Flores-Estrada
    Oscar Arrieta
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 681 - 690
12345